New antigenic targets and methodological approaches for refining laboratory diagnosis of antiphospholipid syndrome

Journal of Immunology Research

Volumn 2015, Issue , 2015, Pages

  Misasi, Roberta ^a   Capozzi, Antonella ^a   Longo, Agostina ^a   Recalchi, Serena ^a   Lococo, Emanuela ^a   Alessandri, Cristiano ^a   Conti, Fabrizio ^a   Valesini, Guido ^a   Sorice, Maurizio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN; CARDIOLIPIN ANTIBODY; LIPOCORTIN 2; LIPOCORTIN 2 ANTIBODY; LIPOCORTIN 5; LIPOCORTIN 5 ANTIBODY; PHOSPHATIDYLSERINE; PHOSPHOLIPID ANTIBODY; PROTEIN ANTIBODY; PROTEIN C; PROTEIN C ANTIBODY; PROTEIN S; PROTEIN S ANTIBODY; PROTHROMBIN; PROTHROMBIN ANTIBODY; UNCLASSIFIED DRUG; VIMENTIN;

ANTIBODY SPECIFICITY; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ANTIPHOSPHOLIPID SYNDROME; CHEMOLUMINESCENCE; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LABORATORY DIAGNOSIS; REVIEW; THIN LAYER CHROMATOGRAPHY; THROMBOSIS; TROPHOBLAST; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; LABORATORY TEST; LUMINESCENCE; PROCEDURES;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; CARDIOLIPINS; CHROMATOGRAPHY, THIN LAYER; CLINICAL LABORATORY TECHNIQUES; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; LUMINESCENT MEASUREMENTS; VIMENTIN;

EID: 84926443381     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2015/858542     Document Type: Review

References (120)

1. G. R. V. Hughes, "The anticardiolipin syndrome," Clinical and Experimental Rheumatology, Vol. 3, no. 4, pp. 285-286, 1985.
2. G. R. Hughes, N. N. Harris, and A. E. Gharavi, "The anticardiolipin syndrome," The Journal of Rheumatology, Vol. 13, no. 3, pp. 486-489, 1986.
3. R. A. Asherson, M. A. Khamashta, and J. Ordi-Ros, "The primary antiphospolipid syndrome: major clinical and serological features," Medicine, Vol. 68, no. 6, pp. 366-374, 1989.
4. W. Lim, "Antiphospholipid syndrome," Hematology, Vol. 2013, no. 1, pp. 675-680, 2013.
5. S. Miyakis, M. D. Lockshin, T. Atsumi et al., "International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)," Journal of Thrombosis and Haemostasis, Vol. 4, no. 2, pp. 295-306, 2006.
6. E. J. Favaloro and R. C. W. Wong, "Antiphospholipid antibody testing for the antiphospholipid syndrome: a comprehensive practical review including a synopsis of chellenges and recent guidelines," Pathology, Vol. 46, no. 6, pp. 481-495, 2014.
7. P. G. de Groot and R. T. Urbanus, "The future of antiphospholipid antibody testing," Seminars in Thrombosis and Hemostasis, Vol. 38, no. 4, pp. 412-420, 2012.
8. K. Otomo, T. Atsumi, O. Amengual et al., "Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events," Arthritis & Rheumatism, Vol. 64, no. 2, pp. 504-512, 2012.
9. Ç. Agar, G. M. A. Van Os, M. Mörgelin et al., "Beta2-Glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome," Blood, Vol. 116, no. 8, pp. 1336-1343, 2010.
10. Y. Shoenfeld, G. Twig, U. Katz, and Y. Sherer, "Autoantibody explosion in antiphospholipid syndrome," Journal of Autoimmunity, Vol. 30, no. 1-2, pp. 74-83, 2008.
11. S. Sciascia, G. Sanna, V. Murru, D. Roccatello, M. A. Khamashta, and M. L. Bertolaccini, "Anti-prothrombin (aPT) and antiphosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review," Thrombosis and Haemostasis, Vol. 111, no. 2, pp. 354-364, 2013.
12. E. Ortona, A. Capozzi, T. Colasanti et al., "Vimentin/cardiolipin complex as a new antigenic target of the antiphospholipid syndrome," Blood, Vol. 116, no. 16, pp. 2960-2967, 2010.
13. M. Sorice, T. Griggi, A. Circella et al., "Protein S antibodies in acquired protein S deficiencies," Blood, Vol. 83, no. 8, pp. 2383-2384, 1994.
14. J. Arachchillage, M. Efthymiou, I. J. Mackie, A. S. Lawrie, S. J. Machin, and H. Cohen, "Anti-protein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic phenotype in antiphospholipid syndrome," Journal of Thrombosis and Haemostasis, Vol. 12, no. 11, pp. 1801-1809, 2014.
15. J. Kaburaki, M. Kuwana, M. Yamamoto, S. Kawai, and Y. Ikeda, "Clinical significance of anti-annexin V antibodies in patients with systemic lupus erythematosus," American Journal of Hematology, Vol. 54, no. 3, pp. 209-213, 1997.
16. V. Salle, J. C. Mazière, A. Smail et al., "Anti-annexin II antibodies in systemic autoimmune diseases and antiphospholipid syndrome," Journal of Clinical Immunology, Vol. 28, no. 4, pp. 291-297, 2008.
17. T. Kobayashi, E. Stang, K. S. Fang, P. de Moerloose, R. G. Parton, and J. Gruenberg, "A lipid associated with the antiphospholipid syndrome regulates endosome structure and function," Nature, Vol. 392, no. 6672, pp. 193-197, 1998.
18. C. Alessandri, M. Bombardieri, L. di Prospero et al., "Antilysobisphosphatidic acid antibodies in patients with antiphos-pholipid syndrome and systemic lupus erythematosus," Clinical and Experimental Immunology, Vol. 140, no. 1, pp. 173-180, 2005.
19. M. Merten, S. Motamedy, S. Ramamurthy, F. C. Arnett, and P. Thiagarajan, "Sulfatides targets for antiphospholipid antibodies," Circulation, Vol. 108, no. 17, pp. 2082-2087, 2003.
20. H. P. McNeil, R. J. Simpson, C. N. Chesterman, and S. A. Krilis, "Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H)," Proceedings of the National Academy of Sciences of the United States of America, Vol. 87, no. 11, pp. 4120-4124, 1990.
21. 2-glycoprotein I: evolution, structure and function," Journal of Thrombosis and Haemostasis, Vol. 9, no. 7, pp. 1275-1284, 2011.
22. M. Sorice, A. Longo, A. Capozzi et al., "Anti-β2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor α and tissue factor by signal transduction pathways involving lipid rafts," Arthritis & Rheumatism, Vol. 56, no. 8, pp. 2687-2697, 2007.
23. T. Colasanti, C. Alessandri, A. Capozzi et al., "Autoantibodies specific to a peptide of β2-glycoprotein I cross-react with TLR4, inducing a proinflammatory phenotype in endothelial cells and monocytes," Blood, Vol. 120, no. 16, pp. 3360-3370, 2012.
24. D. Lopez, K. Kobayashi, J. T. Merrill, E. Matsuura, and L. R. Lopez, "IgG autoantibodies against beta2-glycoprotein I complexed with a lipid ligand derived from oxidized low-density lipoprotein are associated with arterial thrombosis in antiphospholipid syndrome," Clinical and Developmental Immunology, Vol. 10, no. 2-4, pp. 203-211, 2003.
25. R. C. W. Wong, E. J. Favaloro, S. Adelstein et al., "Consensus guidelines on anti-beta 2 glycoprotein I testing and reporting," Pathology, Vol. 40, no. 1, pp. 58-63, 2008.
26. R. T. Urbanus, B. Siegerink, M. Roest, F. R. Rosendaal, P. G. de Groot, and A. Algra, "Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study," The Lancet Neurology, Vol. 8, no. 11, pp. 998-1005, 2009.
27. C. Neville, J. Rauch, J. Kassis et al., "Antiphospholipid antibodies predict imminent vascular events independently from other risk factors in a prospective cohort," Thrombosis and Haemostasis, Vol. 101, no. 1, pp. 100-107, 2009.
28. M. Barbhaiya and D. Erkan, "Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand?" Current Rheumatology Reports, Vol. 13, no. 1, pp. 59-69, 2011.
29. T. Koike, K. Ichikawa, T. Atsumi, H. Kasahara, and E. Matsuura, "β2-Glycoprotein I-anti-β2-glycoprotein I interaction," Journal of Autoimmunity, Vol. 15, no. 2, pp. 97-100, 2000.
30. G. M. Iverson, E. Matsuura, E. J. Victoria, K. A. Cockerill, and M. D. Linnik, "The orientation of beta2GPI on the plate is important for the binding of anti-beta2GPI autoantibodies by ELISA," Journal of Autoimmunity, Vol. 18, no. 4, pp. 289-297, 2002.
31. G. M. Iverson, E. J. Victoria, and D. M. Marquis, "Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI," Proceedings of the National Academy of Sciences of the United States of America, Vol. 95, no. 26, pp. 15542-15546, 1998.
32. B. de Laat and P. G. de Groot, "Autoantibodies directed against domain i of beta2-glycoprotein I," Current Rheumatology Reports, Vol. 13, no. 1, pp. 70-76, 2011.
33. B. de Laat, V. Pengo, I. Pabinger et al., "The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study," Journal of Thrombosis and Haemostasis, Vol. 7, no. 11, pp. 1767-1773, 2009.
34. N. Agnon-Levin, L. Seguro, C. Rosario et al., "Anti-2-GPI-DI antibodies are a marker of APS severity," Arthritis & Rheumatology, Vol. 65, supplement 10, p. 1, 2013.
35. Y. Ioannou, C. Pericleous, I. Giles, D. S. Latchman, D. A. Isenberg, and A. Rahman, "Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2) glycoprotein I: mutation studies including residues R39 to R43," Arthritis and Rheumatism, Vol. 56, no. 1, pp. 280-290, 2007.
36. C. Agostinis, P. Durigutto, D. Sblattero et al., "A human monoclonal antibody against domain I of 2-glycoprotein I prevents clotting and fetal loss induced by polyclonal anti-phospholipid antibodies in animal models," Arthritis & Rheumatology, Vol. 65, p. 5245, 2013.
37. C. Nalli, L. Andreoli, M. Motta et al., "Fine specificity of anti-β2 glycoprotein I antibodies in systemic autoimmune diseases is mostly directed against domain 1," Reumatismo, Vol. 63, no. 2, pp. 91-96, 2011.
38. M. Mahler, G. L. Norman, P. L. Meroni, and M. Khamashta, "Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome," Autoimmunity Reviews, Vol. 12, no. 2, pp. 313-317, 2012.
39. S. S. Pierangeli, X. W. Liu, J. H. Barker, G. Anderson, and E. N. Harris, "Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome," Thrombosis and Haemostasis, Vol. 74, no. 5, pp. 1361-1367, 1995.
40. A. Danowski, T. S. Kickler, and M. Petri, "Anti-β 2-glycoprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus," The Journal of Rheumatology, Vol. 33, no. 9, pp. 1775-1779, 2006.
41. M. L. Bertolaccini, O. Amengual, T. Atsumi et al., "'Non-criteria' aPL tests: Report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010," Lupus, Vol. 20, no. 2, pp. 191-205, 2011.
42. R. Ruiz-García, M. Serrano, J. Ángel Martínez-Flores et al., "Isolated IgA anti-β2 Glycoprotein i antibodies in patients with clinical criteria for antiphospholipid syndrome," Journal of Immunology Research, Vol. 2014, Article ID 704395, 8 pages, 2014.
43. H. L. Staub, G. L. Norman, T. Crowther et al., "Antibodies to the atherosclerotic plaque components beta2-glycoprotein I and heat-shock proteins as risk factors for acute cerebral ischemia," Arquivos de Neuro-Psiquiatria, Vol. 61, no. 3, pp. 757-763, 2003.
44. J. D. Oosting, R. H. W. M. Derksen, I. W. G. Bobbink, T. M. Hackeng, B. N. Bouma, and P. G. de Groot, "Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism?" Blood, Vol. 81, no. 10, pp. 2618-2625, 1993.
45. M. Torricelli, L. Sabatini, P. Florio et al., "Levels of antibodies against protein C and protein S in pregnancy and in preeclampsia," Journal of Maternal-Fetal and Neonatal Medicine, Vol. 22, no. 11, pp. 993-999, 2009.
46. M. Sorice, P. Arcieri, T. Griggi et al., "Inhibition of protein S by autoantibodies in patients with acquired protein S deficiency," Thrombosis and Haemostasis, Vol. 75, no. 4, pp. 555-559, 1996.
47. R. Forastiero, M. Martinuzzo, G. Pombo et al., "A prospective study of antibodies to β2-glycoprotein I and prothrombin, and risk of thrombosis," Journal of Thrombosis and Haemostasis, Vol. 3, no. 6, pp. 1231-1238, 2005.
48. N. Bizzaro, A. Ghirardello, S. Zampieri et al., "Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-year longitudinal study," Journal of Thrombosis and Haemostasis, Vol. 5, no. 6, pp. 1158-1164, 2007.
49. M. L. Bertolaccini, T. Atsumi, T. Koike, G. R. V. Hughes, and M.A. Khamashta, "Antiprothrombin antibodies detectedintwo different assay systems. Prevalence and clinical significance in systemic lupus erythematosus," Thrombosis and Haemostasis, Vol. 93, no. 2, pp. 289-297, 2005.
50. F. Conti, A. Capozzi, S. Truglia et al., "The mosaic of 'seronegative' antiphospholipid syndrome," Journal of Immunology Research, Vol. 2014, Article ID 389601, 7 pages, 2014.
51. E. Boilard, S. G. Bourgoin, C. Bernatchez, and M. E. Surette, "Identification of an autoantigen on the surface of apoptotic human T cells as a new protein interacting with inflammatory group IIA phospholipase A2," Blood, Vol. 102, no. 8, pp. 2901-2909, 2003.
52. N. Mor-Vaknin, A. Punturieri, K. Sitwala, and D. M. Markovitz, "Vimentin is secreted by activated macrophages," Nature Cell Biology, Vol. 5, no. 1, pp. 59-63, 2003.
53. T. J. Podor, D. Singh, P. Chindemi et al., "Vimentin exposed on activated platelets and platelet microparticles localizes vitronectin and plasminogen activator inhibitor complexes on their surface," The Journal of Biological Chemistry, Vol. 277, no. 9, pp. 7529-7539, 2002.
54. B. Xu, R. M. DeWaal, N. Mor-Vaknin, C. Hibbard, D. M. Markovitz, and M. L. Kahn, "The endothelial cell-specific antibody PAL-E identifies a secreted form of vimentin in the blood vasculature," Molecular and Cellular Biology, Vol. 24, no. 20, pp. 9198-9206, 2004.
55. S. Thébault, D. Gilbert, M. Hubert et al., "Orderly pattern of development of the autoantibody response in (New Zealand White × BXSB)F1 lupus mice: characterization of target antigens and antigen spreading by two-dimensional gel electrophoresis and mass spectrometry," Journal of Immunology, Vol. 169, no. 7, pp. 4046-4053, 2002.
56. Z. Romay-Penabad, M. G. Montiel-Manzano, T. Shilagard et al., "Annexin A2 is involved in antiphospholipid antibodymediated pathogenic effects in vitro and in vivo," Blood, Vol. 114, no. 14, pp. 3074-3083, 2009.
57. K. L. Allen, F. V. Fonseca, V. Betapudi, B. Willard, J. Zhang, and K. R. McCrae, "A novel pathway for human endothelial cell activation by antiphospholipid/anti-β2 glycoprotein I antibodies," Blood, Vol. 119, no. 3, pp. 884-893, 2012.
58. F. Cañas, L. Simonin, F. Couturaud, and Y. Renaudineau, "Annexin A2 autoantibodies in thrombosis and autoimmune diseases," Thrombosis Research, Vol. 135, no. 2, pp. 226-230, 2015.
59. G. Cesarman-Maus, N. P. Ríos-Luna, A. B. Deora et al., "Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome," Blood, Vol. 107, no. 11, pp. 4375-4382, 2006.
60. M. L. Bertolaccini, O. Amengual, L. Andreoli et al., "14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends," Autoimmunity Reviews, Vol. 13, no. 9, pp. 917-930, 2014.
61. D. W. Branch, R. Silver, S. Pierangeli, I. van Leeuwen, and E. N. Harris, "Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome," Obstetrics & Gynecology, Vol. 89, no. 4, pp. 549-555, 1997.
62. M. L. Bertolaccini, B. Roch, O. Amengual, T. Atsumi, M. A. Khamashta, and G. R. V. Hughes, "Multiple antiphospholipid tests do not increase the diagnostic yield in antiphospholipid syndrome," British Journal of Rheumatology, Vol. 37, no. 11, pp. 1229-1232, 1998.
63. L. Fialová, L. Mikulíková, I. Matouš-Malbohan, O. Beněsová, and A. Zwinger, "Prevalence of various antiphospholipid antibodies in pregnant women," Physiological Research, Vol. 49, no. 3, pp. 299-305, 2000.
64. R. D. Franklin and W. H. Kutteh, "Antiphospholipid antibodies (APA) and recurrent pregnancy loss: treating a unique APA positive population," Human Reproduction, Vol. 17, no. 11, pp. 2981-2985, 2002.
65. H. Katsuragawa, H. Kanzaki, T. Inoue, T. Hirano, T. Mori, and N. S. Rote, "Monoclonal antibody against phosphatidylserine inhibits in vitro human trophoblastic hormone production and invasion," Biology of Reproduction, Vol. 56, no. 1, pp. 50-58, 1997.
66. A. E. Gharavi, E. N. Harris, R. A. Asherson, and G. R. V. Hughes, "Anticardiolipin antibodies: isotype distribution and phospholipid specificity," Annals of the Rheumatic Diseases, Vol. 46, no. 1, pp. 1-6, 1987.
67. A. E. Tebo, T. D. Jaskowski, A. R. Phansalkar, C. M. Litwin, D. W. Branch, and H. R. Hill, "Diagnostic performance of phospholipid-specific assays for the evaluation of antiphospholipid syndrome," The American Journal of Clinical Pathology, Vol. 129, no. 6, pp. 870-875, 2008.
68. A. E. Tebo, T. D. Jaskowski, H. R. Hill, and D. W. Branch, "Clinical relevance of multiple antibody specificity testing in anti-phospholipid syndrome and recurrent pregnancy loss," Clinical and Experimental Immunology, Vol. 154, no. 3, pp. 332-338, 2008.
69. J.-C. Gris, I. Quéré, M. Sanmarco et al., "Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early foetal loss. The Nimes obstetricians and Haematologists Study - NOHA," Thrombosis and Haemostasis, Vol. 84, no. 2, pp. 228-236, 2000.
70. T. Sugi, H. Matsubayashi, A. Inomo, L. Dan, and T. Makino, "Antiphosphatidylethanolamine antibodies in recurrent early pregnancy loss and mid-to-late pregnancy loss," Journal of Obstetrics and Gynaecology Research, Vol. 30, no. 4, pp. 326-332, 2004.
71. M. Sanmarco, S. Gayet, M.-C. Alessi et al., "Antiphosphati-dylethanolamine antibodies are associated with an increased odds ratio for thrombosis - a multicenter study with the participation of the European Forum on antiphospholipid antibodies," Thrombosis and Haemostasis, Vol. 97, no. 6, pp. 949-954, 2007.
72. M. Sanmarco, "ELISA for antiphosphatidylethanolamine antibody detection: high impact of assay buffer on results," Journal of Immunological Methods, Vol. 358, no. 1-2, pp. 9-16, 2010.
73. J. Gruenberg and T. E. Kreis, "Membranes and sorting," Current Opinion in Cell Biology, Vol. 7, no. 4, pp. 519-522, 1995.
74. B. Galve-de Rochemonteix, T. Kobayashi, C. Rosnoblet et al., "Interaction of anti-phospholipid antibodies with late endosomes of human endothelial cells," Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 20, no. 2, pp. 563-574, 2000.
75. G. Valesini and C. Alessandri, "New facet of antiphospholipid antibodies," Annals of the New York Academy of Sciences, Vol. 1051, pp. 487-497, 2005.
76. 2-GPI accumulation in late endosomes of endothelial cells induced by anti-LBPA antibodies," Thrombosis and Haemostasis, Vol. 87, no. 4, pp. 735-741, 2002.
77. S. Olivieri, A. Ruffatti, A. Bontadi et al., "Clinical value of antibodies to lysobisphosphatidic acid in patients with primary antiphospholipid sindrome," Reumatismo, Vol. 62, no. 2, pp. 107-112, 2010.
78. M. L. Bertolaccini, G. R. V. Hughes, and M. A. Khamashta, "Revisiting antiphospholipid antibodies: from targeting phospholipids to phospholipid binding proteins," Clinical Laboratory, Vol. 50, no. 11-12, pp. 653-665, 2004.
79. F. H. Passam and S. A. Krilis, "Laboratory tests for the antiphos-pholipid syndrome: current concepts," Pathology, Vol. 36, no. 2, pp. 129-138, 2004.
80. K. Oku, T. Atsumi, O. Amengual, and T. Koike, "Antiprothrombin antibody testing: detection and clinical utility," Seminars in Thrombosis and Hemostasis, Vol. 34, no. 4, pp. 335-339, 2008.
81. K. Devreese and M. F. Hoylaerts, "Laboratory diagnosis of the antiphospholipid syndrome: a plethora of obstacles to overcome," European Journal of Haematology, Vol. 83, no. 1, pp. 1-16, 2009.
82. L. Persijn, A. S. Decavele, S. Schouwers, and K. Devreese, "Evaluation of a new set of automated chemiluminescense assays for anticardiolipin and anti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome," Thrombosis Research, Vol. 128, no. 6, pp. 565-569, 2011.
83. F. van Hoecke, L. Persijn, A.-S. Decavele, and K. Devreese, "Performance of two new, automated chemiluminescence assay panels for anticardiolipin and anti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome," International Journal of Laboratory Hematology, Vol. 34, no. 6, pp. 630-640, 2012.
84. A. Capozzi, E. Lococo, M. Grasso et al., "Detection of antiphospholipid antibodies by automated chemiluminescence assay," Journal of Immunological Methods, Vol. 379, no. 1-2, pp. 48-52, 2012.
85. F. Capuano, V. Grasso, L. Belforte et al., "Development of automated assays for anticardiolipin antibodies determination: addressing antigen and standardization issues," Annals of the New York Academy of Sciences, Vol. 1109, no. 1, pp. 493-502, 2007.
86. P. de Moerloose, G. Reber, J. Musial, and J. Arnout, "Analytical and clinical performance of a new, automated assay panel for the diagnosis of antiphospholipid syndrome," Journal of Thrombosis and Haemostasis, Vol. 8, no. 7, pp. 1540-1546, 2010.
87. D. Noubouossie, J. Valsamis, F. Corazza, L. Rozen, F. Debaugnies, and A. Demulder, "An automated chemiluminescence immunoassay may detect mostly relevant IgG anticardiolipin antibodies according to revised Sydney criteria.," Acta clinica Belgica, Vol. 67, no. 3, pp. 184-189, 2012.
88. K. Conrad, H. Schneider, T. Ziemssen et al., "A new line immunoassay for the multiparametric detection of antiganglioside autoantibodies in patients with autoimmune peripheral neuropathies," Annals of the New York Academy of Sciences, Vol. 1109, pp. 256-264, 2007.
89. K. Conrad, D. Roggenbuck, A. Ittenson, D. Reinhold, T. Buettner, and M. W. Laass, "A new dot immunoassay for simultaneous detection of celiac specific antibodies and IgA-deficiency," Clinical Chemistry and Laboratory Medicine, Vol. 50, no. 2, pp. 337-343, 2012.
90. K. Egerer, D. Roggenbuck, T. Büttner et al., "Single-step autoantibody profiling in antiphospholipid syndrome using a multiline dot assay," Arthritis Research and Therapy, Vol. 13, no. 4, article R118, 2011.
91. 2-GPI) assayed by ELISA and dot blot," Clinical & Experimental Immunology, Vol. 118, no. 3, pp. 480-486, 1999.
92. E. M. Bevers, R. F. A. Zwaal, and G. M. Willems, "The effect of phospholipids on the formation of immune complexes between autoantibodies and beta2-glycoprotein I or prothrombin," Clinical Immunology, Vol. 112, no. 2, pp. 150-160, 2004.
93. J. Metzger, P. von Landenberg, M. Kehrel, A. Buhl, K. J. Lackner, and P. B. Luppa, "Biosensor analysis of beta2-glycoprotein Ireactive autoantibodies: evidence for isotype-specific binding and differentiation of pathogenic from infection-induced antibodies," Clinical Chemistry, Vol. 53, no. 6, pp. 1137-1143, 2007.
94. K. Conrad, D. Roggenbuck, D. Reinhold, and T. Dörner, "Profiling of rheumatoid arthritis associated autoantibodies," Autoimmunity Reviews, Vol. 9, no. 6, pp. 431-435, 2010.
95. P. von Landenberg, J. Schölmerich, J. von Kempis, and K. J. Lackner, "The combination of different antiphospholipid antibody subgroups in the sera of patients with autoimmune diseases is a strong predictor for thrombosis. A retrospective study from a single center," Immunobiology, Vol. 207, no. 1, pp. 65-71, 2003.
96. V. Pengo, A. Biasiolo, C. Pegoraro, U. Cucchini, F. Noventa, and S. Iliceto, "Antibody profiles for the diagnosis of antiphospholipid syndrome," Thrombosis and Haemostasis, Vol. 93, no. 6, pp. 1147-1152, 2005.
97. M. Sorice, T. Griggi, A. Circella et al., "Detection of antiphospholipid antibodies by immunostaining on thin layer chromatography plates," Journal of Immunological Methods, Vol. 173, no. 1, pp. 49-54, 1994.
98. F. Conti, C. Alessandri, F. R. Spinelli et al., "TLC immunostaining for detection of 'antiphospholipid' antibodies," Methods in Molecular Biology, Vol. 1134, pp. 95-101, 2014.
99. M. Sorice, V. Pittoni, T. Griggi et al., "Specificity of antiphospholipid antibodies in infectious mononucleosis: a role for anti-cofactor protein antibodies," Clinical and Experimental Immunology, Vol. 120, no. 2, pp. 301-306, 2000.
100. C. Alessandri, M. Sorice, M. Bombardieri et al., "Antiphospholipid reactivity against cardiolipin metabolites occurring during endothelial cell apoptosis," Arthritis Research and Therapy, Vol. 8, article R180, 2006.
101. F. Conti, C. Alessandri, M. Sorice et al., "Thin-layer chromatography immunostaining in detecting anti-phospholipid antibodies in seronegative anti-phospholipid syndrome," Clinical & Experimental Immunology, Vol. 167, no. 3, pp. 429-437, 2012.
102. R. Nayfe, I. Uthman, J. Aoun, E. S. Aldin, M. Merashli, and M. A. Khamashta, "Seronegative antiphospholipid syndrome," Rheumatology, Vol. 52, no. 8, Article ID ket126, pp. 1358-1367, 2013.
103. C. Alessandri, F. Conti, P. Conigliaro, R. Mancini, L. Massaro, and G. Valesini, "Seronegative autoimmune diseases," Annals of the New York Academy of Sciences, Vol. 1173, pp. 52-59, 2009.
104. G. R. V. Hughes and M. A. Khamashta, "Seronegative antiphospholipid syndrome," Annals of the Rheumatic Diseases, Vol. 62, no. 12, p. 1127, 2003.
105. R. Cervera, F. Conti, A. Doria, L. Iaccarino, and G. Valesini, "Does seronegative antiphospholipid syndrome really exist?" Autoimmunity Reviews, Vol. 11, no. 8, pp. 581-584, 2012.
106. M. L. Bertolaccini, S. Gomez, J. F. P. Pareja et al., "Antiphospholipid antibody tests: spreading the net," Annals of the Rheumatic Diseases, Vol. 64, no. 11, pp. 1639-1643, 2005.
107. P. L. Meroni, C. B. Chighizola, F. Rovelli, and M. Gerosa, "Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers," Arthritis Research and Therapy, Vol. 16, no. 2, article 209, 2014.
108. B. de Laat, K. Mertens, and P. G. de Groot, "Mechanisms of disease: antiphospholipid antibodies - from clinical association to pathologic mechanism," Nature Clinical Practice Rheumatology, Vol. 4, no. 4, pp. 192-199, 2008.
109. M. Galli, "Interpretation and recommended testing for antiphospholipid antibodies," Seminars in Thrombosis and Hemostasis, Vol. 38, no. 4, pp. 348-352, 2012.
110. V. Pengo, A. Banzato, E. Bison, A. Bracco, G. Denas, and A. Ruffatti, "What have we learned about antiphospholipid syndrome from patients and antiphospholipid carrier cohorts?" Seminars in Thrombosis and Hemostasis, Vol. 38, no. 4, pp. 322-327, 2012.
111. V. Pengo, A. Ruffatti, T. Del Ross et al., "Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile," Journal of Thrombosis and Haemostasis, Vol. 11, no. 8, pp. 1527-1531, 2013.
112. V. Pengo, A. Ruffatti, C. Legnani et al., "Clinical course of high-risk patients diagnosed with antiphospholipid syndrome," Journal of Thrombosis and Haemostasis, Vol. 8, no. 2, pp. 237-242, 2010.
113. E. J. Favaloro, "Variability and diagnostic utility of antiphospholipid antibodies including lupus anticoagulants," International Journal of Laboratory Hematology, Vol. 35, no. 3, pp. 269-274, 2013.
114. A. Ruffatti, A. Calligaro, A. Hoxha et al., "Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome," Arthritis Care and Research, Vol. 62, no. 3, pp. 302-307, 2010.
115. S. Sciascia, G. Sanna, V. Murru, D. Roccatello, M. A. Khamashta, and M. L. Bertolaccini, "GAPSS: the global anti-phospholipid syndrome score," Rheumatology, Vol. 52, no. 8, pp. 1397-1403, 2013.
116. E. N. Harris, J. K. H. Chan, R. A. Asherson, V. R. Aber, A. E. Gharavi, and G. R. Hughes, "Thrombosis, recurrent fetal loss, and thrombocytopenia. Predictive value of the anticardiolipin antibody test," Archives of Internal Medicine, Vol. 146, no. 11, pp. 2153-2156, 1986.
117. M. Galli, L. Ruggeri, and T. Barbui, "Differential effects of anti-β2-glycoprotein I and antiprothrombin antibodies on the anticoagulant activity of activated protein C," Blood, Vol. 91, no. 6, pp. 1999-2004, 1998.
118. L. Cousins, C. Pericleous, M. Khamashta et al., "Antibodies to domain I of β-2-glycoprotein I and IgA antiphospholipid antibodies in patients with 'seronegative' antiphospholipid syndrome," Annals of the Rheumatic Diseases, Vol. 74, no. 1, pp. 317-319, 2014.
119. M. Samarkos, R. A. Asherson, and S. Loizou, "The clinical significance of IgA antiphospholipid antibodies," The Journal of Rheumatology, Vol. 28, no. 4, pp. 694-697, 2001.
120. A. Satoh, K. Suzuki, E. Takayama et al., "Detection of antiannexin IV and V antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus," The Journal of Rheumatology, Vol. 26, no. 8, pp. 1715-1720, 1999.